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Abstract
For over two decades clinical studies have been conducted which suggest the existence of a
relationship between depression and Obstructive Sleep Apnea (OSA). Recently, Ohayon
underscored the evidence for a link between these two disorders in the general population,
showing that 800 out of 100,000 individuals had both, a breathing-related sleep disorder and a
major depressive disorder, with up to 20% of the subjects presenting with one of these disorders
also having the other. In some populations, depending on age, gender and other demographic and
health characteristics, the prevalence of both disorders may be even higher: OSA may affect more
than 50% of individuals over the age of 65, and significant depressive symptoms may be present in
as many as 26% of a community-dwelling population of older adults.
In clinical practice, the presence of depressive symptomatology is often considered in patients with
OSA, and may be accounted for and followed-up when considering treatment approaches and
response to treatment. On the other hand, sleep problems and specifically OSA are rarely assessed
on a regular basis in patients with a depressive disorder. However, OSA might not only be
associated with a depressive syndrome, but its presence may also be responsible for failure to
respond to appropriate pharmacological treatment. Furthermore, an undiagnosed OSA might be
exacerbated by adjunct treatments to antidepressant medications, such as benzodiazepines.
Increased awareness of the relationship between depression and OSA might significantly improve
diagnostic accuracy as well as treatment outcome for both disorders. In this review, we will
summarize important findings in the current literature regarding the association between
depression and OSA, and the possible mechanisms by which both disorders interact. Implications
for clinical practice will be discussed.
Depression in OSA
Definition and prevalence of OSA
OSA is by far the most common form of sleep disordered
breathing and is defined by frequent episodes of
obstructed breathing during sleep. Specifically, it is char-
acterized by sleep-related decreases (hypopneas) or
pauses (apneas) in respiration. An obstructive apnea is
defined as at least 10 seconds interruption of oronasal air-
flow, corresponding to a complete obstruction of the
upper airways, despite continuous chest and abdominal
movements, and associated with a decrease in oxygen sat-
uration and/or arousals from sleep. An obstructive hypop-
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nea is defined as at least 10 seconds of partial obstruction
of the upper airways, resulting in an at least 50% decrease
in oronasal airflow.
Clinically OSA is suspected when a patient presents with
both snoring and excessive daytime sleepiness (EDS)
[1,2]. The diagnosis of OSA is confirmed when a polysom-
nography recording determines an Apnea-Hypopnea-
Index (AHI) of > 5 per hour of sleep [3]. Even if cutoff
points have never been clearly defined, an AHI of less than
5 is generally considered being normal, 5–15 mild, 15–30
moderate and over 30 severe OSA.
The prevalence of OSA is higher in men than in women.
OSA is found in all age groups but its prevalence increases
with age. In children, the prevalence of OSA is less well
defined and has been estimated to be 2–8% [4]. In sub-
jects between the ages of 30 to 65 years, 24% of men and
9% of women had OSA [5]. Among subjects over 55 years
of age, 30–60% fulfil the criterion of an AHI > 5 [6-8]. In
a population of community-dwelling older adults, 70% of
men and 56% of women between the ages of 65 to 99
years have evidence of OSA with a criterion of AHI > 10
[9].
The abnormal respiratory events which are the hallmark
of OSA are generally accompanied by heart rate variability
and arousals from sleep, with frequent arousals being the
most important factor resulting in EDS. With regards to
sleep architecture, we find a significant increase in light
sleep stage (mainly stage 1) at the expense of deep slow
wave sleep (stages 3 and 4) and REM sleep. Slow wave
sleep is sometimes even completely abolished. However
clinically, patients are often not aware of this repetitive
sleep interruption (with sometimes hundreds of arousals
during one night), but simply do not feel restored in the
morning. Other nocturnal symptoms can include restless-
ness, nocturia, excessive salivation and sweating, gastro-
esophageal reflux, as well as headache and dry mouth or
throat in the morning on awakening.
The extent to which daytime functioning is affected gener-
ally depends on the severity of OSA. Symptoms other than
EDS which greatly impact daytime functioning are neu-
ropsychological symptoms such as irritability, difficulty
concentrating, cognitive impairment, depressive symp-
toms, and other psychological disturbances. Thus, OSA
can easily mimic symptoms of a major depressive episode.
Correlation studies of OSA and depression
Among the first studies investigating the relation between
OSA and depression, Guilleminault et al. [10] reported
that 24% of 25 male patients with OSA had previously
seen a psychiatrist for anxiety or depression, and Reynolds
et al. [11] showed that around 40% of 25 male OSA
patients met the research diagnostic criteria for an affec-
tive disorder, with a higher risk of depression in those
patients who were sleepier during the day. Similarly, Mill-
mann et al. observed that 45% of his 55 OSA patients had
depressive symptoms on the Zung Self-Rating Depression
Scale, with the group scoring higher for depression also
having a significantly higher AHI [12]. Whereas only 26%
of OSA patients described themselves as currently
depressed, 58% fulfilled DSM-III criteria for major depres-
sion of four or more depressive symptoms [13]. Others
observed increased depression scores on the Minnesota
Multiphasic Personality Inventory (MMPI) in patients
with OSA [14,15]. Indeed, Ramos Platon et al. found ele-
vations in several MMPI scales in 23 OSA patients (mod-
erate to high severity) compared to 17 controls [16].
Aikens et al. [17] showed that 32% of their OSA patients
had elevated depression scores on the MMPI and in the
same series of studies, there were twice as many OSA
patients with elevated depression scores than age and sex
matched primary snorers [18]. However, the percentage of
depressive symptoms was not significantly different when
compared to patients with other primary sleep disorders,
such as periodic limb movements during sleep (PLMS)
[19]. Most recently, in an epidemiological study of 18,980
subjects representative of the general population in their
respective countries (UK, Germany, Italy, Portugal, and
Spain) and assessed by cross-sectional telephone survey,
Ohayon determined that 17.6% of subjects with a DSM-
IV breathing-related sleep disorder diagnosis also pre-
sented with a major depressive disorder diagnosis, and
vice versa [20]. This correlation persisted after controlling
for obesity and hypertension.
In contrast to the numerous studies observing a positive
correlation between OSA and depression, some investiga-
tions found no association between both disorders. In a 5-
year longitudinal study, Phillips et al. did not find any sig-
nificant depressive symptoms in elderly patients with a
relatively mild OSA (AHI>5/h), when compared to a con-
trol group without OSA (AHI<5/h) [21]. However, there
are multiple limitations to this study, besides a relatively
small sample size for group comparisons and a non-rep-
resentative study population. OSA was only assessed at
baseline, but not repeated at the five-year follow-up, i.e.
neuropsychological data were compared between two
groups based on OSA status five years earlier. Second,
OSA severity was mild even in the OSA group. Third, the
groups differed significantly by age, with the OSA group
being older than the control group. Finally, the attrition
rate over the five years was very high with only 42 out of
the initial 95 subjects completing the follow-up assess-
ment. In another large-scale study, Pillar and Lavie did not
observe any association between respiratory disturbances
and Symptom Check List 90 in 2,271 predominantly male
patients assessed for OSA [22]. However, the SCL-90 ques-Annals of General Psychiatry 2005, 4:13 http://www.annals-general-psychiatry.com/content/4/1/13
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tionnaire was developed as a screening tool for psychiatric
patients, and not for a normal study population. There-
fore, it might be a less sensitive tool with regards to milder
forms of mood disturbances than other scales. Interest-
ingly, Pillar and Lavie observed that among the minority
of women in this study, those with severe OSA had higher
depression scores than those with mild OSA. Bardwell
found that other factors such as age, body mass index
(BMI) and hypertension accounted for the correlation
between sleep parameters and total mood disturbances in
72 OSA patients when compared to 40 controls [23].
However, the chosen cutoff point to distinguish between
OSA and the control group in this study was relatively
high (AHI of 15/h), thus subjects with a mild OSA were
probably included in the control group.
In sum, the majority of studies to date report an associa-
tion between depression and OSA, but methodological
considerations render the comparison between investiga-
tions difficult. Some of the mixed findings among studies
can be explained by differences in sample size, study pop-
ulation, gender distribution, age and AHI cut-off in rela-
tion to age, as well as variability in terms of the
questionnaires and scales used to assess depressive symp-
tomatology. Given the heterogeneity of these data and
considering the numerous confounding factors, future
longitudinal studies of patient populations are required to
better understand the relation between both disorders.
Treatment Studies for OSA: reversibility of depressive 
symptoms?
The gold standard treatment for moderate to severe cases
of OSAS is continuous or bilevel positive airway pressure
(CPAP/BiPAP) which mechanically maintains the upper
airways space open during sleep via the administration of
ambient air with a certain pressure. The minimum neces-
sary pressure level has to be titrated individually for each
patient [24]. Other treatments, especially for mild cases of
OSA, include weight loss, dental devices (which advance
the tongue or mandible to increase posterior airway
space) or upper airway surgery (e.g. combined tonsillec-
tomy/ adenoidectomy, nasal reconstruction, and uvu-
lopalatopharyngoplasty). Different upper airway surgical
procedures can be used for particular cases with craniofa-
cial abnormalities [25].
Overall, CPAP treatment studies for OSA and its effect on
depressive symptoms have yielded controversial findings.
Derderian et al. [26] compared results on the Profile of
Moods Questionnaire before and after 2 months of CPAP
treatment in an OSA group (n = 7) and showed a signifi-
cant drop in Total Mood Disturbance. This improvement
was correlated with an increase in slow-wave sleep. Those
patients in the study of Millmann et al. who received
CPAP displayed a significant decrease in their Zung
Depression Scale scores [12]. Similarly, Engleman et al.
reported an improvement in a comprehensive battery of
mood and cognitive assessment scales after 4 weeks of
CPAP treatment in 32 patients with moderate OSA [27] as
well as in 16 patients with a mild OSA [28]. Means et al.
[29] showed an improvement on Beck Depression Inven-
tory (BDI) depression scores after 3 months of treatment
in 39 OSA patients, and Sanchez et al. [30] confirmed
lower BDI scores after 1 and 3 months of CPAP therapy in
51 OSA patients. Ramos Platon et al. [16] underscored the
progressive improvement in depression scores on the
MMPI scale over the first year of treatment. A systematic
review on the influence of CPAP on neurobehavioral per-
formance of patients with OSA also supported the clinical
perspective that typically depressive symptoms remit
together with EDS under CPAP therapy [31].
Among the negative studies on CPAP therapy and its effect
on depression, Borak et al. [32] did not observe any
improvement in emotional status after 3 and 12 months
of CPAP therapy in 20 patients with severe OSA, similar to
Munoz et al. [33] who also did not show improvement of
BDI scores in 80 subjects with severe OSA after 12 months
of CPAP. Using subtherapeutic CPAP as the placebo con-
trol, Yu et al. [34] and Henke et al. [35] found no differ-
ence in improvement on depression scores between the
treatment and the control group, over a short treatment
duration (1–3 weeks). However, whereas Borak, Munoz
and Henke do not find any effect of CPAP therapy on
mood, Yu observed a positive effect on mood of both
CPAP therapy and the subtherapeutic CPAP control
group.
Intriguingly, there are no systematic differences with
regards to the sample size, the initial severity of OSA or
the duration of CPAP therapy which might explain the dif-
ferences between studies observing an improvement after
CPAP therapy and those who did not. Several issues have
to be considered: First, it is difficult to design a good con-
trol ("placebo") condition for CPAP treatment. "Sham-
CPAP" which uses insufficient positive airway pressure as
a placebo condition (1 – 2 cm H20), is now used more fre-
quently. Two of the negative studies employed this
method for their control group, which raises the possibil-
ity that the previously observed positive effects of CPAP
on mood may have been a placebo effect. Second, compli-
ance to CPAP treatment is problematic, because patients
have to wear a nasal or even an oranasal device during the
entire night. The compliance may even be particularly
decreased in depressed patients. Indeed, Edinger et al.
[36] reported a positive correlation between lower depres-
sion scores on the MMPI prior to treatment and CPAP
compliance at 6 months of treatment in 28 patients. How-
ever, Lewis et al. [37] did not find any association between
baseline depression scores and subsequent CPAP use forAnnals of General Psychiatry 2005, 4:13 http://www.annals-general-psychiatry.com/content/4/1/13
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the first month of treatment. The most important factor to
explain the differences among these studies may be the
variability in the severity of initial depressive symptoms.
Whereas the severity of OSA itself does not seem to have a
differential impact on mood improvement after CPAP
therapy, the severity of depressive symptoms associated
with OSA may impact response to CPAP treatment. As
Millmann indicates, OSA patients with more severe mood
symptoms responded better to CPAP treatment, whereas
patients with less severe or no mood symptoms actually
had less benefit from CPAP therapy [12]. However, all
negative treatment studies either excluded subjects suffer-
ing from a major depressive disorder, or their depression
scores were even at baseline in a normal range (baseline
values: mean BDI of 7.5 in [32], mean depression score on
POMS scale of 12.5 in [34], mean BDI of 8 in [33], and no
information given on assessed GDS scores in [35]). Future
studies should seek to include OSA patients with a
broader range of depressive symptoms in treatment stud-
ies, to investigate whether CPAP might have a better effect
on mood in more depressed OSA patients.
OSA in depression
Compared to the large number of studies investigating
depressive symptomatology in OSA patients, far fewer
studies have focused on the screening for OSA in a prima-
rily depressed study population. In one of the few investi-
gations of the prevalence of OSA in a depressed cohort,
Reynolds et al. found, in a small sample of 17 older
patients with major depression, that 17.6% also had an
OSA syndrome, compared to 4.3% of 23 healthy elderly
controls [38]. This suggests that OSA might be an impor-
tant confounding factor for studies on mood disorders in
general, as its presence is not routinely determined in
either research studies examining mood or clinical set-
tings. However, many more studies are required to assess
the prevalence of OSA in primarily depressed patients,
particularly as it can be suspected from existing studies
that OSA is greatly underdiagnosed in this patient popu-
lation.
Clinically, this is of particular concern, as sedative antide-
pressants and adjunct treatments for depression may actu-
ally exacerbate OSA. Notably hypnotics prescribed to treat
depression-related insomnia might further decrease the
muscle tone in the already functionally impaired upper
airway dilatator muscles, blunt the arousal response to
hypoxia and hypercapnia as well as increase the arousal
threshold for the apneic event, therefore increasing the
number and duration of apneas [39,40]. These effects
might differ depending on the patient population and the
severity of OSA. Older depressive subjects are of primary
concern: both, frequency of OSA and depressive symp-
toms increase with age, as do prescription and consump-
tion of sedative psychotropic medication. Pharmacologic
treatment of depression and depression-related insomnia
in this age group should therefore routinely consider the
potential presence of a concomitant OSA.
Finally, as Baran and Richert point out, the diagnosis of a
mood disorder in the presence of OSA has its very own
challenges [41]. Considering the DSM-IV definitions [42],
it could either be viewed as a mood disorder due to a gen-
eral medical condition, or classified as an adjustment dis-
order with depressed mood, due in particular to EDS and
its debilitating consequences on the patients' daytime
functioning. The identification of pathophysiological fea-
tures that allow distinction between OSA and depression
might assist with such diagnostic issues.
Sleep architecture in depression and OSA
Both depression and OSA have been well characterized
with regards to their sleep architecture. Typically, for
major depression, polysomnography (PSG) findings con-
firm the patients' complaints of insomnia, notably diffi-
culties falling asleep (PSG: increase in sleep latency),
frequent awakenings during the night and early morning
awakenings (PSG: idem) as well as non-refreshing sleep
(PSG: decrease in slow wave sleep). PSG furthermore
reveals a shortened REM latency, i.e. the first episode of
REM sleep appears earlier than usual, with an increase in
total percentage of REM sleep during the night, as well as
in its eye movement density (referred to as REM sleep dis-
inhibition) [43]. On the other hand, the sleep of patients
with OSA is fragmented, and contains a lot of transitional
sleep stages (stage 1) at the expense of REM sleep and par-
ticularly of slow wave sleep (stages 3 and 4) [44,45]. At
least two studies have investigated sleep architecture at the
interplay of OSA and depression or depressive symptoms.
Reynolds et al. stated that, in contrast to the sleep EEG of
depressed patients which characteristically shows a
shorter latency of REM sleep, sleep apnea patients with
depression displayed an increase in REM latency [11].
Bardwell et al. compared a group of 106 patients with and
without OSA with regards to their sleep architecture.
Depressed patients who also had OSA displayed a
decrease in sleep latency when compared to the depressed
group without OSA; and OSA subjects with depressive
symptoms had a higher percentage of REM sleep than
OSA subjects without depression [46]. Rather than distin-
guishing a primary depressive illness from an organic
affective syndrome related to OSA [11], however, the
aforementioned polysomnographic results underscore
how both disorders interplay, thus confounding EEG
findings characteristic for each disorder.Annals of General Psychiatry 2005, 4:13 http://www.annals-general-psychiatry.com/content/4/1/13
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Possible mechanisms underlying the association 
between depression and OSA
Sleep fragmentation and hypoxemia
The two main factors suspected to be responsible for
depressive symptoms in OSA are sleep fragmentation and
oxygen desaturation during sleep. Sleep fragmentation is
a direct consequence of the recurrent microarousals asso-
ciated with the apneas and hypopneas, and the nocturnal
hypoxemia is due to the intermittent drops in oxygen sat-
uration caused by the respiratory events [47]. Sleep frag-
mentation is the primary cause of EDS in OSA patients,
and is suggested to result in the depressive symptomatol-
ogy in OSA. This last perspective gains support from the
finding that EDS as measured by the Epworth Sleepiness
Scale (ESS) and the Maintenance of Wakefulness Test
(MWT) was found to be correlated with higher depression
scores on the Hospital Depression Scale (HAD-D) in 44
patients with OSA [48]. Furthermore, a Canadian study
on 30 OSA patients showed a significant correlation
between the severity of psychological symptoms on SCL-
90 and less total sleep time, as well as percentage of wake
time after sleep onset and ESS scores [49]. With respect to
hypoxemia, Engleman et al. noted in a recent review that
the effect size of cognitive impairment in OSA correlated
highly with severity of hypoxic events, ranging from .3
standard deviations for milder levels of AHI to 2–3 stand-
ard deviations for higher levels of AHI [50]. Recently, pre-
liminary imaging data suggests that hypoxemia related to
OSA might also play a role in impacting mood. Cerebral
metabolic impairment resulting from recurrent nocturnal
hypoxemia in OSA have had previously been observed in
several imaging investigations on OSA [51-53]; independ-
ently, white matter hyperintensities (WMH) have been
linked to depressive symptomatology in studies on affec-
tive disorders [54-58]. Aloia et al. reported in a small sam-
ple of older patients with OSA more subcortical WMH in
the brain MRI of patients with a severe OSA as compared
to those with minimal OSA, and a tendency for a positive
correlation between these subcortical hyperintensities
and depression scores on the Hamilton Depression Scale
[59].
Neurobiology of depression and upper airway control in OSA: the role 
of serotonin
The high comorbidity of OSA and depression also sug-
gests that both disorders may share a common neurobio-
logical risk factor. On the neurotransmitter level, the
serotoninergic system has a central role as a neurobiologi-
cal substrate underlying impairments in the regulations of
mood, sleep-wakefulness cycle, and upper airway muscle
tone control during sleep. Depression is associated with a
functional decrease of serotoninergic neurotransmission,
and is mostly responsible for the alterations in sleep as
outlined above [60].
The physiopathology of OSA involves numerous factors,
among whose the abnormal pharyngeal collapsibility
during sleep is one of the most compelling. Serotonin
delivery to upper airway dilatator motor neurons has been
shown to be reduced in dependency of the vigilance state
[61]. This leads to reductions in dilator muscle activity
specifically during sleep, which may contribute to sleep
apnea. However, whereas the role of serotonin in mood
disorders has been largely documented, its involvement
in the pathophysiology of sleep apnea remains to be clar-
ified. Interestingly, molecules increasing 5-HT neurotrans-
mission such as the Serotonin reuptake inhibitors (SSRI)
are widely prescribed antidepressant molecules that are
suggested to similarly improve the apnea hypopnea index
in OSA. Serotoninergic drugs such as fluoxetine, protryp-
tiline and paroxetine have already been tested for OSA,
with limited success and numerous adverse effects [61].
Several 5-HT receptor ligands and bi-functional molecules
are under development, which may in the future be able
to target both, the depressive syndrome and OSA.
Shared risk factors
OSA and depression share common risk factors, which
may partly explain their high comorbidity in the general
population. Very frequently in studies of the impact of
OSA on cognitive and psychological functioning, a con-
glomerate of disorders is shown to contribute to the over-
all neuropsychological outcome. Therefore, the presence
of a polypathology often associated with OSA, such as
obesity, cardiovascular disease, hypertension and diabe-
tes, should increase the suspicion of an underlying or
coexisting OSA in a depressed patient.
Both, depression and OSA, have independently been
shown to be associated with metabolic syndrome, and
also with the development of cardiovascular disease
[62,63]. The association between depression and meta-
bolic syndrome has been suggested to be reciprocal [64],
and a priori not attributable to genetic factors as twin
studies revealed [65]. In particular, insulin resistance (IR)
has been suggested to contribute to the pathophysiology
of depressive disorder and has been proposed to subserve
the association between depression and cardiovascular
disease [66]. Similarly, OSA has been observed to be inde-
pendently associated with the cardiovascular risk factors
comprising metabolic syndrome [67], in particular IR
[68]. The magnitude of this association has even led
researchers to suggest that metabolic syndrome should
encompass OSA [69].
Although OSA and depression share these common risk
factors, there are currently no studies available which have
investigated the issue of antecedent or consequence in the
relationship between depression, OSA and metabolic syn-
drome, and if and how these three highly prevalent disor-Annals of General Psychiatry 2005, 4:13 http://www.annals-general-psychiatry.com/content/4/1/13
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ders may interact to exacerbate the risk for cardio – and
cerebrovascular morbidity and mortality.
Clinical application
As a consequence of the complex relationship between
depression and OSA, the assessment of a patient's individ-
ual sleep history should be included in the standard psy-
chiatric clinical interview, and specifically in the
assessment of a depressive syndrome. A clinician should
suspect OSA particularly in those depressed patients who
present with its cardinal symptoms, namely, 1) loud snor-
ing or intermittent pauses in respiration, as witnessed by
a bed partner, associated with 2) excessive daytime sleep-
iness (EDS). Given that patients often deny the latter,
standardized questionnaires such as the Epworth Sleepi-
ness Scale (ESS) [70] or the Functional Outcome Sleep
Questionnaire (FOSQ) [71] are useful tools to assess EDS.
The ESS asks the patients to rate their chances to fall asleep
during periods of relaxation or inactivity (such as reading,
watching television), but also in more active settings
(driving a car, sitting and talking to someone). EDS is by
far the most frequent daytime symptom of OSA, whereas
nocturnal symptoms include restlessness, nocturia, exces-
sive salivation and sweating, gastroesophageal reflux, as
well as headache and dry mouth or throat in the morning
on awakening. Furthermore, the clinical picture fre-
quently includes obesity and hypertension, and, in those
patients who are not obese, special facial abnormalities
which narrow the upper airway, such as retrognathia or
micrognathia.
However, it should be kept in mind that OSA may not be
immediately apparent, but might present in an atypical
fashion, with irritability, tiredness, disrupted sleep, diffi-
culty concentrating, difficulties accomplishing tasks and
generally decreased psychomotor performance [12].
Women are more likely to present with these symptoms
[22,72,73], and have been suggested to be particularly
underdiagnosed because of their atypical symptoms [74].
The importance of the sleep-wake complaints in a
patient's depressive profile, and the onset of those com-
plaints prior to the development of the depressive psycho-
pathology should draw the clinician's attention to a
potential underlying or coexisting OSA [75].
Third, particular attention should be paid to depressive
patients who are resistant to treatment. In this case, OSA
should be excluded as a major underlying contributing
factor [76], as treatment of OSA could improve not only
the compliance to pharmacological antidepressant treat-
ment, but also the treatment response rate for depression
[77]. Fourth, comorbid disorders of OSA may also catch
the attention of the treating psychiatrist. In addition to the
outlined association with the metabolic syndrome, Farney
et al. observed that the likelihood of OSA increased signif-
icantly when either antihypertensive or antidepressant
medications had been prescribed [78].
Depressed patients with a suspected OSA should be
referred to a sleep disorders center for evaluation by noc-
turnal polysomnography, to confirm the diagnosis of OSA
or the presence of other forms of sleep disordered breath-
ing, such as the upper airway resistance syndrome [79].
This is of particular importance, as some of the adjunct
treatments to the current pharmacological treatment of
depression may actually exacerbate the condition.
If the diagnosis of OSA has been established in a
depressed patient, and treatment has been initiated, close
follow-up of the improvement of the depressive symp-
toms might give some indications as to the extent to
which the presence of OSA may have contributed to the
depressive symptomatology. However, as Baran and Rich-
ert point out [41], the aforementioned diagnostic chal-
lenge of a depressive syndrome in the presence of OSA
currently remains unresolved.
On the other hand, systematic assessment of depressive
symptoms with standardized clinical questionnaires in
OSA patients is generally part of the evaluation process in
all major sleep disorder centers. However, as these ques-
tionnaires have not been specifically designed to assess
depression in OSA patients [80], they might be inappro-
priate to assess depression in this population, given that it
is still unclear if OSA and depression display a true comor-
bidity or only share similar symptoms [41]. Typically,
patients with severe depressive symptoms should be
referred to a psychiatrist, particularly if such symptoms do
not regress or if fatigue lingers after efficient treatment of
OSA [81].
Conclusion
Recent studies underscore the existence of a complex rela-
tionship between depression and OSA in terms of clinical
presentation, underlying pathophysiology and treatment.
It should incite the treating psychiatrist to be highly aware
of a possibly underlying or coexisting OSA in depressed
patients. Up to 20% of all patients presenting with a diag-
nosed depressive syndrome may also have OSA, and vice
versa. This relationship might vary widely, depending on
age, gender, AHI cut-off and general demographic and
health characteristics of the population under investiga-
tion. Future clinical research in this area should specifi-
cally examine depressed patient populations, taking into
account the different sub-type of mood disorders, and
investigate a broader range of depressive symptomatology
in OSA patients. Basic research should further investigate
the causal relationship between depression and OSA, as
well as the potential mechanisms by which both disorders
may interact.Annals of General Psychiatry 2005, 4:13 http://www.annals-general-psychiatry.com/content/4/1/13
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